Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2019

View Archived Issues

"Love hormone" causes heartbreak -- literally

Improving Imbruvica

Identification of a novel potent EML4-ALK inhibitor for non-small cell lung carcinoma

Inebilizumab demonstrates safety and efficacy in phase III N-MOmentum study

Batavia Biosciences and University of Tokyo to develop a vector-based vaccine against Nipah virus

AMS-0421, an aptamer targeting VEGF-A for retinal disease

Protagonist Therapeutics presents phase I data for PN-943

Tolimidone leads to significant reduction of HbA1c in phase IIb trial in type 2 diabetes

Angex Pharmaceutical identifies indoleamine 2,3-dioxygenase 1 inhibitors

Advent Pharma discovers fibroblast growth factor receptor 4 inhibitors

New vasopressin V1A and V2 receptor antagonists described by Bayer

Hitgen patents histone deacetylase inhibitors

Beijing Yuezhikangtai Biomedicines discloses AXL and/or c-Met inhibitors

Integrator proteins shown to resist nerve cell regression

Flotillin-1/2 as a novel target in patients with CNS inflammatory conditions

AEA, PEA and OEA as promising novel biomarkers for autism spectrum disorder

Alzheimer's candidate PRI-002 completes phase I testing

Precision BioSciences describes ARCUS gene editing strategy for hepatitis B

Mutation in ROBO1 gene tied to development of CPHD

FDA approves Bavencio with Inlyta for advanced renal cell carcinoma

Sanofi doses first patient in phase IIb study of SAR-442168 for relapsing MS

Encouraging phase I data reported for dAd5GNE anti-cocaine vaccine

Sienna reports biopsy data from phase IIb study of SNA-120 for psoriasis

DSMB recommends continuation of phase II study of SENS-111 in acute unilateral vestibulopathy

Allegro reports promising results from proof-of-concept study of ALG-007 in dry eye disease

Phase III study of abrocitinib in atopic dermatitis meets all coprimary and secondary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...